Clinical trials: Resistant Depression, Treatment
Major Depressive Disorder
Ketamine in Adolescents With Treatment-Resistant Depression
This study will test the use of ketamine for treatment of depression in adolescents that have not responded to other treatments. We will also examine neurobiological mechanisms of treatment.
- Trial name
- NCT02078817
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Treatment Resistant Depression
BPL-003 Efficacy and Safety in Treatment Resistant Depression
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
- Trial name
- NCT05870540
- Testing
- BPL-003
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Beckley Psytech Limited
Posttraumatic Stress Disorder
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01793610
- Testing
- Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Resilient Pharmaceuticals
Bipolar Disorder
Radiosurgical Neuromodulation for Refractory Depression
This study is designed to evaluate the safety and effectiveness of an investigational procedure for treating people with treatment resistant bipolar depression (TRD).
- Trial name
- NCT01403441
- Testing
- Radiosurgical Neuromodulation using the Cyberknife
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Depression
Mifepristone in Refractory Depression
The purpose of the study is to examine the effectiveness of mifepristone treatment in patients with refractory depression. Refractory depression is defined as clinical depression that is unimproved after treatment with at least 2…
- Trial name
- NCT00186056
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Stanford University
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Bipolar Disorder, Insulin Resistance
Pioglitazone for the Treatment of Bipolar Depression
The primary objective is to test the hypothesis that adjunctive pioglitazone is more effective than placebo for the relief of acute depressive symptoms resulting from bipolar disorder.
- Trial name
- NCT01717040
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University Hospitals Cleveland Medical Center
Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant
Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression
The long term follow up of a pilot study in which the investigators proposed to test whether high frequency stimulation of the subcallosal cingulate (SCC) is a safe and efficacious antidepressant treatment in five TRD patients…
- Conditions
- Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
- Trial name
- NCT03360942
- Testing
- SCC DBS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
- Trial name
- P-TRD (NCT03775200)
- Testing
- Psilocybin
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 233 people
- Sponsor
- COMPASS Pathways
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Depression, Treatment Resistant Depression
Intensive TMS for Bipolar Depression
The research study is being conducted to test whether using high dose spaced theta-burst rTMS (a form of transcranial magnetic stimulation) produces a significant reduction in depressive symptoms compared with sham.
- Trial name
- NCT05228457
- Testing
- Intensive intermittent theta-burst stimulation (iTBS)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Pennsylvania
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression, Major Depressive Disorder
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
In this proof of concept study, the investigators plan to administer iv ketamine interleaved with ECT days. Patients with treatment resistant depression who are deemed to be eligible for ECT treatment will randomly be assigned to…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT02522377
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Major Depressive Disorder
PET Biomarkers in Treatment Resistant Depression
The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment…
- Trial name
- NCT01031810
- Testing
- tranylcypromine
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression
Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression.
- Trial name
- NCT00837486
- Testing
- Reclaim™ DBS System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedtronicNeuro
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.
- Trial name
- NARSAD (NCT03283670)
- Testing
- Nitrous Oxide 25%, Nitrous Oxide 50%
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine